Abbott and Dexcom,two leaders in the continuous glucose monitor market,today struck a settlement agreement for ongoing patent litigation.

雅培和Dexcom这两家连续血糖监测仪市场的领先企业今天就正在进行的专利诉讼达成了和解协议。

Our sibling site,Drug Delivery Business News,reports today that the companies settled all outstanding patent disputes between them.

我们的兄弟网站Drug Delivery Business News今天报道说，这两家公司解决了它们之间所有悬而未决的专利纠纷

The patent litigation relates to the companies’continuous glucose monitor(CGM)technologies.The companies and Dexcom are two leaders in the CGM space.They offer market-leading platforms,with Abbott’s FreeStyle Libre 3 and Dexcom’s G7 representing their latest-generation technologies.

专利诉讼与两家公司的连续血糖监测仪(CGM)技术有关。这两家公司和Dexcom是CGM领域的两大领军企业。它们提供市场领先的平台，雅培的FreeStyle Libre 3和Dexcom的G7代表了它们最新一代的技术。

News of the settlement comes within a few weeks of a Unified Patent Court decision that sided with Abbott following a CGM patent infringement claim from Dexcom.Dexcom requested that the court find infringement with the LibrelinkUp remote analyte monitoring system.The court revoked EP282 in its entirety across the contracting member states in Europe as specified by Abbott’s request.It dismissed all of Dexcom’s infringement claims based on the patent at issue.

在Dexcom提出CGM专利侵权索赔后的几周内，统一专利法院做出了支持雅培的判决，雅培与Dexcom达成和解的消息不胫而走。Dexcom要求法院认定LibrelinkUp远程分析监测系统侵权。法院根据雅培的请求，在欧洲各签约成员国全面撤销了EP282。法院驳回了Dexcom基于涉案专利提出的所有侵权索赔。